Eagle's Eye View: Your Weekly CV Update From ACC.org

In this week's View, Dr. Eagle looks at how higher whole-grain intake was associated with improvements in multiple cardiometabolic risk factors in a meta-analysis of randomized trials. He then examines how concomitant use of tafamidis or heart failure (HF) therapies did not modify the treatment benefit of vutrisiran on all-cause mortality and recurrent cardiovascular events, according to a HELIOS-B analysis, and follows that with a look in the case of patients with severe asymptomatic carotid artery stenosis, adding revascularization with either carotid artery stenting (CAS) or carotid endarterectomy (CEA) to intensive medical management (IMM) did not improve cognition compared with IMM alone, according to results from the CREST-2 randomized trials. Finally, Dr. Eagle explores how women in the CENTURY trial had higher coronary blood flow (CBF) than men while having a comparable burden of cardiovascular risk factors, similar treatment response and half the coronary events, offering a potential physiological explanation for the delayed clinical manifestation of coronary artery disease (CAD) in women.

Subscribe to Eagle's Eye View

In this week's View, Dr. Eagle looks at a recent JACC: Advances Viewpoint that examines the challenges associated with implementing revisions to the definition of first medical contact (FMC) introduced in the 2025 ACC/AHA ACS Guideline and its implications for NCDR data collection. He then examines a cardiooncology primer on CV toxicity of antibody-drug conjugates (ADCs) in breast cancer and follows that with a look at extreme heat and blood press (BP) changes, especially among the elderly. Finally, Dr. Eagle explores the results of the FinACAF study that indicates patients with atrial flutter only (AFL-only) had a 40% lower risk of ischemic stroke than those with atrial fibrillation only (AFib-only).

Subscribe to Eagle's Eye View

In this week's View, Dr. Eagle looks at a recent article on proposed changes to the current cardiovascular (CV) subspecialty training path. He then examines an article on a novel left atrium (LA) staging framework that stratifies new-onset atrial fibrillation risk in hypertrophic cardiomyopathy (HCM). Finally, Dr. Eagle explores the results of a Look AHEAD ancillary study on the inflammatory biomarker interleukin (IL)-6 that identified residual inflammatory risk of incident heart failure (HF) in patients with type 2 diabetes (T2D) and overweight/obesity.

Subscribe to Eagle's Eye View

In this week's View, Dr. Eagle looks at some of the important trials presented at this year's European Society of Cardiology (ESC) Congress. First, he evaluates the SINGLE-AF trial on DOAC therapy versus no anticoagulation in atrial fibrillation (AFib) with patients with intermediate stroke risk. Dr. Eagle then examines REBOOT-PARADOX and its study of the potential value of transcatheter aortic valve replacement (TAVR) in symptomatic patients with low-flow, low-gradient aortic stenosis. Next, Dr. Eagle covers ViVA, a randomized trial that looked at vericiguat for the treatment of coronary vasospasm, followed by a summary of the REACT trial that investigated the use of imaging to detect silent atherosclerosis in early adulthood. Finally, Dr. Eagle explores NOTION-4, which looks at short-term direct oral anticoagulant (DOAC) therapy and subclinical leaflet thickening after TAVR.

Subscribe to Eagle's Eye View

In this week's View, Dr. Eagle evaluates how sacubitril/valsartan promotes cardiac remodeling, but not functional capacity, in nonobstructive hypertrophic cardiomyopathy. Next, he examines the prognostic value of stress perfusion cardiac magnetic resonance in patients with suspected coronary artery disease. Finally, Dr. Eagle explores a study on mitral transcatheter edge-to-edge repair (M-TEER) and its effectiveness for treatment of patients with ventricular functional mitral regurgitation (MR) and very severe left ventricular (LV) dysfunction.

Subscribe to Eagle's Eye View

In this week's View, Dr. Eagle evaluates how sacubitril/valsartan promotes cardiac remodeling, but not functional capacity, in nonobstructive hypertrophic cardiomyopathy. Next, he examines the prognostic value of stress perfusion cardiac magnetic resonance in patients with suspected coronary artery disease. Finally, Dr. Eagle explores a study on mitral transcatheter edge-to-edge repair (M-TEER) and its effectiveness for treatment of patients with ventricular functional mitral regurgitation (MR) and very severe left ventricular (LV) dysfunction.

Subscribe to Eagle's Eye View

In this week's View, Dr. Eagle looks at the relationship between lower cardiorespiratory fitness (CRF) and higher coronary artery calcium scores (CAC) and later-life dementia. He follows this with a look at a new State of the Art Review related to guidance on treating athletes with arrhythmia. He then offers a perspective on the use of vutrisiran in the treatment of amyloid burden. Finally, Dr. Eagle explores the TARTAN-HF study on NT-proBNP screening and its ability to identify undiagnosed heart failure (HF) among patients with diabetes.

Subscribe to Eagle's Eye View

In this week's View, Dr. Eagle looks at the wide variation in antithrombotic regimens after valve-in-valve transcatheter aortic valve replacement (TAVR). Next, he examines PARTNER-3, a 7-year study on TAVR versus surgical aortic valve replacement (SAVR) outcomes in low-risk patients. He then offers a perspective on the effect of sex difference and delayed diagnosis in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) from amyloidosis. Finally, Dr. Eagle explores the prospective SAMCRO trial which evaluates lifestyle intervention in addition to medical therapy in patients with invasively confirmed angina with no obstructive coronary artery disease (ANOCA).

Subscribe to Eagle's Eye View

In this week's View, Dr. Eagle looks at a post-hoc analysis of the API-CAT trial that showed recurrent venous thromboembolism (VTE) is uncommon but associated with poor short-term survival of patients with cancer-associated thrombosis. He follows with a look at an observational cohort study on how influenza vaccination is associated with lower risks of incident atrial fibrillation (AFib), then reviews evidence from the DAPT-MVD trial demonstrating that extended DAPT lowers the risk of cardiovascular events after percutaneous coronary intervention (PCI) in multivessel coronary artery disease. Finally, Dr. Eagle explores ACC's updated expert consensus decision pathway addressing the management of heart failure preserved ejection fraction (HFpEF).

Subscribe to Eagle's Eye View

In this week's View, Dr. Eagle looks at age, body mass index (BMI), and cardiovascular outcomes after transcatheter aortic valve replacement (TAVR). He follows this with an examination of a new consensus statement about enhanced radiation protection in cath labs, then offers a perspective on particulate matter in the environment and increased coronary heart disease risk. Finally, Dr. Eagle provides an analysis of the SUMMIT Trial, showing the benefit of tirzepatide for heart failure with preserved ejection fraction (HFpEF) both in women and men.

Subscribe to Eagle's Eye View